VivoSeq
Immunology

Giant Cell Arteritis

26

Pipeline Programs↗

9

Active Trials↗

12

Companies Involved↗

Giant Cell Arteritis is an emerging landscape with 26 programs across 12 companies. The most active players are Roche, Regeneron, Alnylam Pharmaceuticals. 1 therapy is approved with 12 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

52/100

Pipeline Velocity

15/100

Mech. Concentration

14/100

Completion Rate

78/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

1 program

Phase 1Regeneron logo

Regeneron

1 program

Phase 2Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 2M

Milestone Pharmaceuticals Inc.

1 program

Phase 2P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

2 programs

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

68%

Small molecule

19 of 28 classified programs — the dominant modality here.

32%ALL OTHERSMonoclonal antibody829%Protein / enzyme14%

Small molecule leads; the ring shows all 28 classified programs, each share of the total. Modality classified for 97% of 31 pipeline programs.

Analysis

Trial Status

36

clinical trials

Completed18 · 50%
Active, not recruiting4 · 11%
Unknown status4 · 11%
Terminated4 · 11%
Recruiting3 · 8%
Not yet recruiting2 · 6%
Other1 · 3%

Clinical Trials

Trial Activity

36 trials

Abatacept for the Treatment of Giant Cell Arteritis
Recruiting·UUniversity of Pennsylvania·Phase 3·NCT04474847·78 enrolled
Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT07108387·78 enrolled
A Randomized, Controled, Open Label Trial: Comparison Between Two Standardized Corticosteroids Tapering, Respectively Short (North American) and Long (European), in Giant Cell Arteritis
Recruiting·UUniversity Hospital, Caen·Phase 3·NCT04012905·150 enrolled
TocilizuMab discontinuAtion in GIant Cell Arteritis
Active, not recruiting·—·Phase 3·NCT06037460·120 enrolled
MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial
Active, not recruiting·—·Phase 3·NCT03892785·230 enrolled
Methotrexate as Remission Maintenance Therapy After Remission-Induction With Tocilizumab and Glucocorticoids in Giant Cell Arteritis
Active, not recruiting·UUniversity of Bonn·Phase 2·NCT05623592·52 enrolled
Efficacy of Tocilizumab in Association to Steroids in Giant Cell Arteritis With Cerebro-vascular Involvement
Active, not recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT04888221·66 enrolled
Bosentan in the Treatment of Giant Cell Arteritis
Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT06957002·40 enrolled
Treatment for Giant Cell Arteritis With Tocilizumab and 8 as Compared to 26 Weeks of Prednisone
Not yet recruiting·IInsel Gruppe AG, University Hospital Bern·Phase 3·NCT06833411·178 enrolled
HECTHOR: Humira to Spare Steroids in Giant Cell Arteritis
Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT00305539·69 enrolled
Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis
Completed·National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)·Phase 2·NCT00556439·97 enrolled
Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Giant Cell Arteritis: Proof of Concept Study.
Completed·—·Phase 2·NCT01910038·20 enrolled
A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis
Completed·AbbVie logoAbbVie·Phase 3·NCT03725202·429 enrolled
Tocilizumab for Patients With Giant Cell Arteritis
Completed·IInsel Gruppe AG, University Hospital Bern·Phase 2·NCT01450137·30 enrolled
Phase II Randomized Study of Glucocorticoids With or Without Methotrexate for Treatment of Giant Cell Arteritis
Completed·TThe Cleveland Clinic·Phase 2·NCT00004686·300 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)